This analysis shows that 62% of the registries are related to oncology products, which is interesting given that the registries started in 2005 for a cancer MP [trastuzumab (Gazzetta Ufficiale, 2005) for the early stage adjuvant therapy in the treatment of HER-2 positive breast cancer]. Here, ERBB2 is linked to breast cancer.